新検索ページはこちら
ログイン
お問い合わせ
（旧版）高血圧治療ガイドライン2004
書誌情報
文献
| 201 ） | Arakawa S, Saku Y, Ibayashi S, Nagao T, Fujishima M: Blood pressure control and recurrence of hypertensive brain hemorrhage. Stroke 1998; 29: 1806-1809. |
| 202 ） | 澤田徹: 無症候性脳血管障害とは-その定義と診断基準-．日内会誌 1997; 86: 725-732. |
| 203 ） | 脳ドックの新ガイドライン作成委員会：脳ドックのガイドライン2003．日本脳ドック学会，北海道，2003. |
| 204 ） | Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S: Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke 1997; 28: 1932-1939. |
| 205 ） | Vermeer SE, Hollander M, van Dijk EJ, Hoffman A, Koudstaal PJ, Breteler MM: Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003; 34: 1126-1129. |
| 206 ） | Vermeer SE, Prins ND, den Heijer T, Koudstaal PJ, Breteler MM: Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348: 1215-1222. |
| 207 ） | Kinoshita T, Okudera T, Tamura H, Ogawa T, Hatazawa J: Assessment of lacunar hemorrhage associated with hypertensive stroke by echo-planar gradient-echo T2*-weighted MRI. Stroke 2000; 31: 1646-1650. |
| 208 ） | Kato H, Izumiyama M, Izumiyama K, Takahashi A, Itoyama Y: Silent cerebral microbleeds on T2*-weighted MRI: correlation with stroke subtype, stroke recurrence, and leukoaraiosis. Stroke 2002; 33: 1536-1540. |
| 209 ） | Leary MC, Saver JL: Annual incidence of first silent stroke in the United States: A preliminary estimates. Cerebrovasc Dis 2003; 16: 280-285. |
| 210 ） | 石井當男: 高血圧薬物療法の変遷と展望. 脈管学 1997; 9: 551. |
| 211 ） | 松沢佑次，久道茂，北徹，小澤秀樹，山村卓：動脈硬化発症に貢献する宿主要因の意義．平成7年度労働省作業関連疾患総合対策研究報告書，1996. |
| 212 ） | Staessen JA, Wang JG, Thijs L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305-1315. |
| 213 ） | Moser M, Hebert P, Hennekens CH: An overview of the meta-analyses of the hypertension treatment trials. Arch Intern Med 1991; 151: 1277-1279. |
| 214 ） | The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial（the EUROPA study）. Lancet 2003; 362: 782-788. |
| 215 ） | Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study（INVEST）: a randomized controlled trial. JAMA 2003; 290: 2805-2816. |
| 216 ） | Kondo J, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, Kono T, Kosaka T, Yoshida T, Numaguchi Y, Matsui H, Murohara T, Okumura K: Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. Am Heart J 2003; 146: E20. |
| 217 ） | Japanese beta-Blockers and Calcium Antagonists Myocardial Infarction（JBCMI）Investigators: Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 2004; 93: 969-973. |
| 218 ） | Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Malcolm J, Arnold O, Wun CC, Davis BR, Braunwald E, for the cholesterol and recurrent events trial investigators: The effect of pravastatin on coronary event after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009. |
| 219 ） | Pedersen TR: Six-year follow-up of the Norwegian Multicenter Study on Timolol after acute myocardial infarction. N Engl J Med 1985; 313: 1055-1058. |
| 220 ） | The CAPRICORN Investigators: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390. |
| 221 ） | The Multicenter Diltiazem Postinfarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385-392. |
| 222 ） | Ishikawa K, Nakai S, Takenaka T, Kanamasa K, Hama J, Ogawa I, Yamamoto T, Oyaizu, M, Kimura A, Yamamoto K, Yabushita H, Katori R, on behalf of the Secondary Prevention Group: Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction. Secondary Prevention Group. Circulation 1997; 95: 2368-2373. |
| 223 ） | 石川欽司，金政健，濱純吉，小川巌，竹中俊彦，木村彰男，香取瞭：高齢者心筋梗塞後患者の二次予防におけるβ遮断薬の効果．日老医誌 1997; 34: 273-277. |
| 224 ） | Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial-the SAVE investigation. N Engl J Med 1992; 327: 669-677. |
| 225 ） | Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Valsaltan in Acute Myocardial Infarction Trial Investigators: Valsaltan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906. |
| 226 ） | Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321. |
| 227 ） | VA Cooperative Study Group on Hypertensive Agents: Effects of treatment on morbidity in hypertension. JAMA 1970; 213: 1143-1152. |
| 228 ） | The SOLVD Investigators: The effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302. |
| 229 ） | The SOLVD Investigators: The effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691. |
| 230 ） | Cohn JN, Tognoni G: Valsaltan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsaltan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675. |
| 231 ） | Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, CHARM Investigators and Committees: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766. |
| 232 ） | Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K, CHARM Investigators and Committees: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-776. |
| 233 ） | Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators and Committees: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular systolic function: the CHARM-Preserved trial. Lancet 2003; 362: 777-781. |
| 234 ） | Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the U.S. Carvedilol heart failure study group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-1355. |
| 235 ） | Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekslaus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Haliman M, Dietz R, Neuhaus KL, Janos A, Thorgeinsson G, Dunseluran PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P: Effects of controlled-release metoprolol on total mortality, hospitalization, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Investigation Trial in congestive heart failure（MERIT-HF）. MERIT-HF Study Group. JAMA 2000; 283: 1295-1302. |
| 236 ） | CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II（CIBIS II）: a randomised trial. Lancet 1999; 353: 9-13. |
| 237 ） | Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tender M, Castaigne A, Staiger C, Curtin EL, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group: Effects of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658. |
| 238 ） | Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldmanmd AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines（Committee to revise the 1995 guidelines for the evaluation and management of heart failure）. Circulation 2001; 104: 2996-3007. |
| 239 ） | Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL, for the prospective randomized amlodipine survival evaluation study group: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-1114. |
| 240 ） | Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48-54. |
| 241 ） | Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertention. Am J Med 2003; 115: 41-46. |
| 242 ） | Sato A, Hayashi M, Saruta T: Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res 2002; 25: 837-842. |
| 243 ） | Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ, for the VA Cooperative Study Group on Antihypertensive Agents: Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Circulation 1997; 95: 2007-2014. |
| 244 ） | Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J, National kidney foundation hypertension and diabetes executive committees working group: Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646-661. |
| 245 ） | Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-18. |
| 246 ） | Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S: Blood pressure predicts risk of development end-stage renal disease in men and women. Hypertension 2003; 41: 1341-1345. |
| 247 ） | Voyaki SM, Staessen JA, Thijs L, Wang JG, Efstratopoulos AD, Birkenhager WT, de Leeuw PW, Leonetti G, Nachev C, Rodicio JL, Tuomilehto J, Fagard R; Systolic Hypertension in Europe（Syst-Eur）Trial Investigators: Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens 2001; 19: 511-519. |
| 248 ） | Vupputuri S, Batuman V, Muntner P, Bazzano LA, Lefante JJ, Whelton PK, He J: Effects of blood pressure on early decline in kidney function among hypertension men. Hypertension 2003; 12: 1144-1149. |
| 249 ） | Levey AS, Coresh J, Balk E, Kausz A, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National kidney foundation practice guideline for chronic kidney disease, Evaluation, Classification, and Stratification. Ann Intern Med 2003; 139: 137-149. |
| 250 ） | Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa D, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease. Hypertension 2003; 11: 1050-1065. |
| 251 ） | Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ: Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63: 1121-1129. |
| 252 ） | Ruilope L, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A: Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment（HOT）Study. J Am Soc Nephrol 2001; 12: 218-225. |
| 253 ） | Hillege HL, Girbes ARJ, Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-210. |
| 254 ） | Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636. |
| 255 ） | Manjunath G, Tighiouart H, Ibrahim H, Macleod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47-55. |
| 256 ） | Iseki K, Ikemiya Y, Iseki C, Takishita S: Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003; 63: 1468-1474. |
| 257 ） | Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment（INSIGHT）. Lancet 2000; 356: 366-372. |
| 258 ） | Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS GROUP: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study（UKPDS 64）. Kidney Int 2003; 63: 225-232. |
| 259 ） | Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S; HOPE Study Investigators: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426. |
| 260 ） | Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Jonssen WM, Grobbee DE, de Jong PE; Prevention of Renal and Vascular End Stage Disease（PREVEND）Study Group: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782. |
| 261 ） | Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S: Influence of smoking and obesity on the development of proteinuria. Kidney Int 2002; 62: 956-962. |
| 262 ） | Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD: Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-1509. |
| 263 ） | Orth SR: Smoking and the kidney. J Am Soc Nephrol 2002; 13: 1663-1672. |
| 264 ） | Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH: The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: A meta-analysis. Ann Intern Med 1996; 124: 627-632. |
| 265 ） | Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL; The Modification of Diet in Renal Disease Study Group: Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995; 123: 754-762. |
| 266 ） | Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition, a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252. |
| 267 ） | Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Gassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: result from the AASK trial. JAMA 2002; 288: 2421-2431. |
| 268 ） | Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, Paul E, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS; AIPRD study group: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60: 1131-1140. |
| 269 ） | Ruggenenti P, Perna A, Remuzzi G; The investigators of the GISEN group: Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003; 63: 2254-2261. |
| 270 ） | Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA: Management of glomerular proteinuria, a commentary. J Am Soc Nephrol 2003; 14: 3217-3232. |
| 271 ） | De Zeeuw D, Remuzzi G, Parving H, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 2004; 65: 2309-2320. |
| 272 ） | Levey AS, Rocco MV: Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1-S268. |
| 273 ） | Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860. |
| 274 ） | Parving HH, Lehnert H, Mortensen JB, Gomis R, Andersen S, Arner P; Irbesartan in Patients with type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878. |
| 275 ） | Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effects of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progress Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939-945. |
| 276 ） | The GISEN Group（Gruppo Italiano di Studi Epidemiologici in Nefrologia）: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 249: 1857-1863. |
| 277 ） | PROCOPA study group: Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease, a randomized double-blind trial. J Hypertens 2002; 20: 729-737. |
| 278 ） | Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease（COOPERATE）, a randomised controlled trial. Lancet 2003; 361: 117-124. |
| 279 ） | Keane WF, Eknoyan G: Proteinuria, risk, assessment, detection, elimination（PARADE）: a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 35: 1004-1010. |
| 280 ） | Mangrum AJ, Bakris GL: Angiotensin-Converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: Safety issue. Semin Nephrol 2004; 24: 168-175. |
| 281 ） | Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS Jr, Rovin BH: Renoprotection: one or many therapies? Kidney Int 2001; 59: 1211-1226. |
| 282 ） | Kumagai H, Hayashi K, Kumamaru H, Saruta T: Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study, Am J Hypertens 2000; 9: 980-985. |
| 283 ） | Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68. |
| 284 ） | White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021-1026. |
| 285 ） | 日本透析医学会統計調査委員会（秋葉隆）：わが国の慢性透析療法の現状（2002年12月31日現在）．日本透析医学会，2003, p12. |
| 286 ） | Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, Van Stone J, Levey A, Meyer KB, Klag MJ, Johnson HK, Clark E, Sadler JH, Teredesai P: ﾒUﾓ curve association of blood pressure and mortality in hemodialysis patients. Kidney Int 1998; 54: 561-569. |
| 287 ） | Mazzuchi N, Carbonell E, Fernandes-Cean J: Importance of blood pressure control in hemodialysis patient survival. Kidney Int 2000; 58: 2147-2154. |
| 288 ） | Kimura G, Tomita J, Nakamura S, Uzu T, Inenaga T: Interaction between hypertension and other cardiovascular risk factors in survival of hemodialyzed patients. Am J Hypertens 1996; 9: 1006-1012. |
| 289 ） | 菊池健次郎, 柊山幸志郎： 透析患者の心機能障害に関する研究． 長期慢性疾患総合研究事業（慢性腎不全）研究報告（総括班長黒川清），1998, pp49-54. |
| 290 ） | Nakamura S, Sasaki O, Nakahama H, Inenaga T, Kimura G: Left ventricular hypertrophy is a risk factor independent of hypertension in survival of hemodialyzed patients. Ren Fail 2002; 24: 175-186. |
| 291 ） | Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C: Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 2002; 61: 2157-2164. |
| 292 ） | Foley RN, Herzog CA, Collins AJ: Blood pressure and long-term mortality in United States hemodialysis patients: USRDA waves 3 and 4 study. Kidney Int 2002; 62: 1784-1790. |
| 293 ） | Efrati S, Zaidenstein R, Dishy V, Beberashvili L, Sharist M, Averbukh Z, Golik A, Weissgarten J: ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002; 40: 1023-1029. |
| 294 ） | Guerin AP, Blacher J, Pannier B, Matchais SJ, Safar ME, London GM: Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001; 20: 987-992. |
| 295 ） | Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T: Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002; 90: 256-261. |
| 296 ） | Suzuki H, Nakamoto H, Okada H, Sugahara S, Kanno Y: A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Adv Perit Dial 2003; 19: 59-66. |
| 297 ） | Saracho R, Martin-Malo A, Martinez I, Aljama P, Montenegro J: Evaluation of the Losartan in Hemodialysis（ELHE）Study. Kidney Int 1998; 68（Suppl）: S125-S129. |
| 298 ） | Wheat MW: Intensive drug therapy. In: Aortic dissection. Edited by Doroghazi RM, Slater E, McGraw-Hill, New York, 1983, p165. |
| 299 ） | Pretre R, von Segesser LK: Aortic dissection. Lancet 1997; 349: 1461-1464. |
| 300 ） | Nienaber CA, Eagle KA: Aortic dissection: New Frontiers in diagnosis and management. Part II: Therapeutic management and follow-up. Circulation 2003; 108: 772-778. |
